Interior of the Old Jersey Prison Ship in the Revolutionary War

https://academic.oup.com/cid/article/82/2/i/8497665?rss=1

[Profile] Reem Abu Shomar— championing water safety in Gaza
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00064-2/fulltext?rss=yes

As a Palestinian female scientist, Reem Abu Shomar experiences repeated trauma thinking of the war in Gaza. An expert in water safety and public health, Shomar spent more than two decades working in this sector in Gaza, and defended her PhD on water technology in September 2023, just weeks before her life and those of all she knew would be changed forever by the war. She is now based in Toronto, Canada, where she continues her public health and water safety research though collaboration with international partners.

[Correspondence] Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00009-5/fulltext?rss=yes

We thank Brenda A Warecki and colleagues for their thoughtful letter on our study on cefiderocol versus standard therapy for Gram-negative bacterial bloodstream infection.1 They question whether the outcome of patients randomly assigned to cefiderocol might have been more favourable if the type of metallo-β-lactamase (MBL) was determined at the initiation of therapy using a rapid molecular diagnostic test, with the implication that patients infected with organisms harbouring NDM genes should have been excluded from the trial.

[Correspondence] Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00008-3/fulltext?rss=yes

David L Paterson and colleagues recently evaluated cefiderocol versus standard-of-care therapy for hospital-acquired and health-care-associated bloodstream infections caused by Gram-negative bacilli.1 This was an international, open-label, parallel-group, randomised clinical trial. 250 patients received cefiderocol and 254 received standard-of-care treatment. Cefiderocol resulted in a non-inferior 14-day mortality compared with standard of care, even within the carbapenem-resistant subset. This interpretation places cefiderocol as effective treatment for Gram-negative bloodstream infections, regardless of the underlying carbapenemase mechanism.

[Comment] Peer review at The Lancet Infectious Diseases in 2025
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00079-4/fulltext?rss=yes

In this issue of The Lancet Infectious Diseases, the editorial team would like to thank all the researchers who peer reviewed for us in 2025. We express our gratitude to the 876 people from 82 countries who peer reviewed at least one article for us in the past year. We are particularly grateful to the peer reviewers who looked at more than one article and/or assessed several revisions. Without their expertise and constructive feedback, we would not be able to publish infectious disease research of the highest quality.

[Comment] Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00072-1/fulltext?rss=yes

Fernando Abad-Franch

[Newsdesk] Controversial HBV vaccine trial in Guinea-Bissau halted
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00075-7/fulltext?rss=yes

A US-funded study in Guinea-Bissau on the effects of neonatal hepatitis B virus vaccination has been suspended pending further review due to ethical concerns. Talha Burki reports.

[Newsdesk] People needing trachoma interventions at record low
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00073-3/fulltext?rss=yes

In January 2026, WHO reported that the number of people requiring interventions for trachoma had fallen below 100 million—a 94% reduction since 2002. Timothy Jesudason reports.

Genetically Similar High-Risk Strains of Carbapenemase-Producing Enterobacterales in Humans and Companion Animals, United States

https://wwwnc.cdc.gov/eid/article/32/3/25-1458_article

Correction: Vol. 32, No. 1

https://wwwnc.cdc.gov/eid/article/32/3/c1-3203_article

Projected Effects of Changing Global Tuberculosis Epidemiology on Mycobacterium tuberculosis Prevalence and Immunoreactivity, 2024–2050

https://wwwnc.cdc.gov/eid/article/32/3/25-1340_article

Rethinking Leptospirosis Prevention, the Philippines

https://wwwnc.cdc.gov/eid/article/32/3/25-1250_article

Romanticism at the Edge of Death

https://wwwnc.cdc.gov/eid/article/32/3/ac-3203_article

Optimal Specimens and Lesions for Mpox Diagnosis Using Real-Time PCR, South Korea

https://wwwnc.cdc.gov/eid/article/32/3/25-0582_article

Rickettsia lanei Rickettsiosis, Oregon, USA, 2025

https://wwwnc.cdc.gov/eid/article/32/4/25-1962_article

Strongyloides Genetic Diversity among Humans, Dogs, and Nonhuman Primates, Central African Republic, 2016–2022

https://wwwnc.cdc.gov/eid/article/32/3/25-0526_article

[Comment] Preventing tuberculosis in advanced HIV disease
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00277-2/fulltext?rss=yes

The persistent and high burden of advanced HIV disease in endemic settings is a major threat to global efforts to reduce AIDS-related hospitalisations and deaths. In 2024, over 600 000 people died from AIDS-related opportunistic infections, with over half of these deaths due to cryptococcal meningitis and tuberculosis. We now have innovative diagnostic, preventive, and therapeutic interventions to combat these diseases, but implementing these new tools among people with advanced HIV presents several enduring challenges.

[Articles] Inpatient initiation of tuberculosis preventive therapy with 1 month of isoniazid and rifapentine for adults with advanced HIV disease and cryptococcal meningitis (IMPROVE): a non-inferiority, randomised controlled trial
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00246-2/fulltext?rss=yes

1HP initiation before hospital discharge was non-inferior to outpatient initiation among adults with AHD and cryptococcosis. These data suggest that following exclusion of active tuberculosis disease, inpatient 1HP initiation is feasible and comparably safe compared with outpatient initiation.

Environmental and Phylogenetic Investigations of Aspergillus flavus Outbreak Linked to Contaminated Building Materials, Denmark, 2025

https://wwwnc.cdc.gov/eid/article/32/3/25-1219_article

Rapid Interventions to Limit Outbreak of Invasive Streptococcus pneumoniae in Correctional Facility, North Carolina, USA, 2024

https://wwwnc.cdc.gov/eid/article/32/3/25-0789_article

Home-Based Monitoring of Treatment-Related Adverse Events during Drug-Resistant Tuberculosis Treatment, India, 2020–2024

https://wwwnc.cdc.gov/eid/article/32/3/25-1893_article